Legend Biotech (LEGN) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street ends down sharply, worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Vertiv shares fall on analyst downgrades and options bets
- Stocks slip as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
JPMorgan on Legend Biotech Corp. (LEGN): 'Remain Confident in Carvykti’s Profile Post ODAC Briefing Docs'
March 13, 2024 12:10 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "While we expect the FDAs question around the imbalance in early death in CARTITUDE-4 to be taken seriously at Fridays ad com on Carvykti, the data around early deaths show it... More



